The standard clinical procedure for diagnosing prostate cancer (PCa) is a systematic transrectal ultrasound-guided (TRUS) biopsy, indicated by an elevated prostate-specific antigen (PSA) level and/or an abnormal digital rectal examination (DRE) [1]. This evidence concerns the gene KLK3 and prostate carcinoma.